Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00427219 · ClinicalTrials.gov registry record · Phase 2
The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate
A Phase 2 study of Benign Prostatic Hypertrophy, sponsored by Spectrum Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
- 13
- Study locations
NCT00427219 is a Phase 2 study of Benign Prostatic Hypertrophy that has completed, run by Spectrum Pharmaceuticals. The registered enrollment target is 74 participants. The trial reports 13 study locations across 10 states.
The verdict
NCT00427219, a Phase 2 study of Benign Prostatic Hypertrophy, has completed, sponsored by Spectrum Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
- 13
- Study locations
Study Summary
This study is to compare the efficacy and safety of ozarelix 15 mg given intramuscular (IM) 2 weeks apart on the improvement of symptoms and the duration of improvement for up to 6 months in men with Benign Prostatic Hypertrophy (BPH) who are over 50 years of age.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ozarelix
Study Locations (13)
California
- Jay Young, MD - Laguna Hills
- Alexander Gershman, MD - Los Angeles
- Stephen Auerbach, MD - Newport Beach
- Eugene Dula, MD - Tarzana
Arizona
- Donald Gleason, MD - Tucson
Colorado
- Joel Kaufman, MD - Aurora
Florida
- Ira Klimberg, MD - Ocala
Idaho
- Joseph Williams, MD - Meridian
Indiana
- Christopher Steidle, MD - Fort Wayne
Missouri
- Steven Bigg, MD - St Louis
New York
- Jed Kaminetsky, MD - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2007-01-23 |
| Est. Completion | 2008-02-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00427219
The ClinicalTrials.gov registry entry for NCT00427219 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spectrum Pharmaceuticals, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Benign Prostatic Hypertrophy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00427219 reports 13 study locations spanning 10 distinct geographic areas - top geographies include California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT00427219 about?
NCT00427219 is a clinical study titled "The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate". This study is to compare the efficacy and safety of ozarelix 15 mg given intramuscular (IM) 2 weeks apart on the improvement of symptoms and the duration of improvement for up to 6 months in men with Benign Prostatic Hypertrophy (BPH) who are over 50 years of age.
What is the current status of trial NCT00427219?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2007-01-23. Estimated completion is 2008-02-27.
What conditions does trial NCT00427219 study?
This clinical trial studies the following conditions: Benign Prostatic Hypertrophy.
What interventions are being tested in trial NCT00427219?
The interventions under investigation include: Placebo (DRUG), Ozarelix (DRUG).
Who is sponsoring clinical trial NCT00427219?
This trial is sponsored by Spectrum Pharmaceuticals, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00427219 being conducted?
This trial has 13 study locations across Arizona, California, Colorado, Florida, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Benign Prostatic Hypertrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.